Scinai Immunotherapeutics Ltd
Scinai Immunotherapeutics Ltd., a biopharmaceutical company, focuses on developing, manufacturing, and commercializing inflammation and immunology biological products for the treatment of infectious and autoimmune diseases in Israel. It develops nanosized VHH antibodies (nanoAbs) targeting diseases with unmet medical needs; and PC111, a monoclonal antibody for treating pemphigus, steven johnson's… Read more
Scinai Immunotherapeutics Ltd (SCNI) - Net Assets
Latest net assets as of June 2025: $7.86 Million USD
Based on the latest financial reports, Scinai Immunotherapeutics Ltd (SCNI) has net assets worth $7.86 Million USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($11.84 Million) and total liabilities ($3.98 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $7.86 Million |
| % of Total Assets | 66.37% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | 15.89% |
| Growth Volatility | 236.03 |
Scinai Immunotherapeutics Ltd - Net Assets Trend (2000–2024)
This chart illustrates how Scinai Immunotherapeutics Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Scinai Immunotherapeutics Ltd (2000–2024)
The table below shows the annual net assets of Scinai Immunotherapeutics Ltd from 2000 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $9.98 Million | +318.36% |
| 2023-12-31 | $-4.57 Million | -159.60% |
| 2022-12-31 | $-1.76 Million | -279.23% |
| 2021-12-31 | $982.00K | +121.62% |
| 2020-12-31 | $-4.54 Million | +75.89% |
| 2019-12-31 | $-18.84 Million | -125.68% |
| 2018-12-31 | $-8.35 Million | -151.63% |
| 2017-12-31 | $16.17 Million | +143.15% |
| 2016-12-31 | $6.65 Million | -22.77% |
| 2015-12-31 | $8.61 Million | +102.23% |
| 2014-12-31 | $4.26 Million | -38.46% |
| 2013-12-31 | $6.92 Million | +16.21% |
| 2012-12-31 | $5.95 Million | -11.33% |
| 2011-12-31 | $6.71 Million | -15.44% |
| 2010-12-31 | $7.94 Million | -5.92% |
| 2009-12-31 | $8.44 Million | +181.28% |
| 2008-12-31 | $3.00 Million | +190.49% |
| 2007-12-31 | $-3.31 Million | -290.08% |
| 2006-12-31 | $1.74 Million | -35.46% |
| 2005-12-31 | $2.70 Million | -34.18% |
| 2004-12-31 | $4.11 Million | +533.49% |
| 2003-12-31 | $648.00K | +620.00% |
| 2002-12-31 | $90.00K | +2350.00% |
| 2001-12-31 | $-4.00K | +83.33% |
| 2000-12-31 | $-24.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Scinai Immunotherapeutics Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 11753900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Comprehensive Income | $-1.74 Million | -17.44% |
| Other Components | $129.26 Million | 1295.54% |
| Total Equity | $9.98 Million | 100.00% |
Scinai Immunotherapeutics Ltd Competitors by Market Cap
The table below lists competitors of Scinai Immunotherapeutics Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
GREEN SHIFT COMMODITIES
F:7WV
|
$2.37 Million |
|
Mekong Fisheries JSC
VN:AAM
|
$2.37 Million |
|
Bounty Oil & Gas NL
PINK:BYOGF
|
$2.38 Million |
|
Canlan Ice Sports Corp
PINK:CNLFF
|
$2.38 Million |
|
Awakn Life Sciences Corp
PINK:AWKNF
|
$2.37 Million |
|
THALES - Dusseldorf Stock Exchang
DU:CSF
|
$2.37 Million |
|
Simble Solutions Ltd
AU:SIS
|
$2.37 Million |
|
Sadot Group Inc.
NASDAQ:SDOT
|
$2.37 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Scinai Immunotherapeutics Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -4,569,000 to 9,977,000, a change of 14,546,000.
- Net income of 4,796,000 contributed positively to equity growth.
- New share issuances of 2,000,000 increased equity.
- Other factors increased equity by 7,750,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $4.80 Million | +48.07% |
| Share Issuances | $2.00 Million | +20.05% |
| Other Changes | $7.75 Million | +77.68% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Scinai Immunotherapeutics Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.06x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-12-31 | $470.40 | $0.71 | x |
| 2009-12-31 | $1103.69 | $0.71 | x |
| 2010-12-31 | $890.61 | $0.71 | x |
| 2011-12-31 | $695.95 | $0.71 | x |
| 2012-12-31 | $565.05 | $0.71 | x |
| 2013-12-31 | $577.06 | $0.71 | x |
| 2014-12-31 | $313.67 | $0.71 | x |
| 2015-12-31 | $326.33 | $0.71 | x |
| 2016-12-31 | $196.86 | $0.71 | x |
| 2017-12-31 | $321.66 | $0.71 | x |
| 2018-12-31 | $-127.72 | $0.71 | x |
| 2019-12-31 | $-230.68 | $0.71 | x |
| 2020-12-31 | $-40.98 | $0.71 | x |
| 2021-12-31 | $6.96 | $0.71 | x |
| 2022-12-31 | $-9.34 | $0.71 | x |
| 2023-12-31 | $-11.70 | $0.71 | x |
| 2024-12-31 | $12.37 | $0.71 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Scinai Immunotherapeutics Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 48.07%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 728.88%
- • Asset Turnover: 0.05x
- • Equity Multiplier: 1.35x
- Recent ROE (48.07%) is above the historical average (-62.69%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | 25.65% | 18.05% | 1.13x | 1.25x | $642.50K |
| 2008 | -40.36% | 0.00% | 0.00x | 1.07x | $-1.51 Million |
| 2009 | -13.81% | 0.00% | 0.00x | 1.06x | $-2.01 Million |
| 2010 | -31.34% | 0.00% | 0.00x | 1.09x | $-3.28 Million |
| 2011 | -32.18% | 0.00% | 0.00x | 1.07x | $-2.83 Million |
| 2012 | -40.79% | 0.00% | 0.00x | 1.05x | $-3.02 Million |
| 2013 | -33.50% | 0.00% | 0.00x | 1.08x | $-3.01 Million |
| 2014 | -46.81% | 0.00% | 0.00x | 1.11x | $-2.42 Million |
| 2015 | -30.40% | 0.00% | 0.00x | 1.23x | $-3.48 Million |
| 2016 | -35.86% | 0.00% | 0.00x | 1.18x | $-3.05 Million |
| 2017 | -61.42% | 0.00% | 0.00x | 1.45x | $-11.55 Million |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-22.62 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-29.74 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-931.88K |
| 2021 | -835.64% | 0.00% | 0.00x | 32.62x | $-8.30 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.62 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-6.04 Million |
| 2024 | 48.07% | 728.88% | 0.05x | 1.35x | $3.80 Million |
Industry Comparison
This section compares Scinai Immunotherapeutics Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Scinai Immunotherapeutics Ltd (SCNI) | $7.86 Million | 25.65% | 0.51x | $2.37 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |